The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in ...

Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient ...

The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...

Aleta Biotherapeutics, a clinical stage immuno-oncology company developing CAR T-cell engager biologics that enable CAR T-cell cancer therapies to work more effectively, and Cancer Research UK’s ...

March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee's approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high ...

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...

Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now ...